Gross Stefan, Rahal Rami, Stransky Nicolas, Lengauer Christoph, Hoeflich Klaus P
J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1.
Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases. Currently, more than 25 oncology drugs that target kinases have been approved, and numerous additional therapeutics are in various stages of clinical evaluation. In this Review, we provide an in-depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in drug discovery, and demonstrate the clinical impact of selective kinase inhibitors. We also describe the substantial progress that has been made in designing next-generation inhibitors to circumvent on-target resistance mechanisms, as well as ongoing strategies for combining kinase inhibitors in the clinic. Last, there are numerous prospects for the discovery of novel kinase targets, and we explore cancer immunotherapy as a new and promising research area for studying kinase biology.
激酶抑制剂在癌症和其他疾病的治疗中发挥着越来越重要的作用。目前,已有超过25种靶向激酶的肿瘤药物获批,还有许多其他疗法正处于临床评估的不同阶段。在本综述中,我们深入分析了癌症中激酶的激活机制,突出了药物研发的近期成果,并展示了选择性激酶抑制剂的临床影响。我们还描述了在设计新一代抑制剂以规避靶向耐药机制方面取得的重大进展,以及激酶抑制剂联合应用的临床策略。最后,发现新型激酶靶点的前景广阔,我们将癌症免疫疗法作为研究激酶生物学的一个新的、有前景的研究领域进行了探讨。